CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 8,505 enrolled
Drug / intervention
Beta blockerdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03596385
NCT03596385Phase 4Completed

TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III·interventional·Posted Jul 23, 2018·Updated Jun 6, 2025

In Brief

A Phase 4 clinical trial evaluating Beta blocker for Myocardial Infarction. Completed, enrolled 8,505 participants across 111 sites in 2 countries.

Detailed Summary

REBOOT clinical trial will study whether long-term maintenance beta-blockers therapy results in a clinical benefit after heart attack without reduced left ventricular function. Half of the participants will be randomized to receive long-term beta-blocker therapy and the other half to no beta-blocker therapy after hospital discharge. All patients will be followed up for up to 5 years to determine the occurrence of adverse events (all cause mortality, re-infarction, and heart failure admission).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly, Spain
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJul 23, 2018
Enrollment StartOct 31, 2018
Primary CompletionJan 31, 2025
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 7.9 years ago

Interventions

Beta blockerdrug

long-term maintenance beta-blocker therapy